Bristol Myers turns attention to new products in wake of Revlimid patent loss

Nicole DeFeudis

Editor

Bristol Myers Squibb CEO Giovanni Caforio is shifting his focus to newer products as generic sales continue to gnaw at the company’s blockbuster myeloma drug Revlimid.

Both Revlimid and Abraxane sales took a dive last year thanks to generic rivals, BMS reported in its Q4 and full-year results on Thursday. As a result, Q4 sales dipped 5% and full-year sales remained flat. However, Caforio sees a silver lining — or rather, two of them.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

view job offer post your job now

TRENDING NOW

Bristol Myers turns attention to new products in wake of Revlimid patent loss

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Bris­tol My­ers turns at­ten­tion to new prod­ucts in wake of Revlim­id patent loss

Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

Bristol Myers turns attention to new products in wake of Revlimid patent loss